Sup19 CAR-T Phase 1 Trial for CD19 Therapy Failures and B-Acute Lymphoblastic Leukemia

NIH added a new Phase 1 clinical trial registration for Sup19 CAR-T cell therapy to ClinicalTrials.gov. The trial targets adult and pediatric patients with B-Acute Lymphoblastic Leukemia or B-ALL/Lymphoma who have experienced failure of prior CD19-targeted therapy or whose tumors express CD19 weakly. The single-arm study will evaluate safety and efficacy endpoints.

Sponsors developing CAR-T or other cell therapy products for hematologic malignancies should be aware that this trial adds to the growing body of clinical evidence for CD19-directed approaches in relapsed/refractory B-ALL populations. Clinical trial sites and institutional review boards may encounter increased interest in CAR-T trial participation as competitor and complementary programs advance through development stages.